# Histone deacetylase inhibitor payloads

Source: https://onco.cc/terms/hdac-inhibitor-payloads/  
OnCo record `hdac-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads alter how tightly genetic instructions are packaged and used. Researchers have attached them to antibodies to test targeted control of cancer-cell behavior.

## Summary

Cetuximab conjugates carrying the histone deacetylase inhibitor ST7612AA1 were studied with cleavable and non-cleavable linkers. The primary report demonstrated changes in histone and tubulin acetylation and antitumor activity in animal models. This supports an epigenetic payload concept even when the unconjugated molecule is less cytotoxic than conventional payloads. Human safety and benefit require separate evaluation.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: HDAC inhibitor payloads; ST7612AA1

## Sources

- Cini et al., antibody delivery of an HDAC inhibitor (2018): https://doi.org/10.1039/c7sc05266a

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)

---
JSON: https://onco.cc/api/v1/entities/hdac-inhibitor-payloads.json